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Introduction: Periodontitis is initiated and sustained by bacteria. However, the mechanism of bacteria induced
periodontitis is still unknown. We hypothesized that bacterial components can affect the functions of stem cells in
the periodontium. In this study, we comparatively investigated the influence of Lipopolysaccharide (LPS) on the
osteogenesis potential of human periodontal ligament stem cells (PDLSCs) and bone marrow mesenchymal stem
cells (BMMSCs).
Methods: Human PDLSCs and BMMSCs were harvested and mineralized nodule formation was assessed by alizarin
red S staining. Expression level of osteogenic related gene was detected by quantitative RT-PCR (qRT-PCR). The
expression of Toll-like receptor 4 (TLR4) and its downstream signaling pathway were examined by western blot. The
role of TLR4 and related signaling pathway in LPS impairing the osteogenic potential of human PDLSCs and
BMMSCs were also studied by alizarin red S staining and qRT-PCR. Experimental periodontitis was induced in adult
Sprague–Dawley rats and the alveolar bone loss was measured by micro computed tomography analysis. The
expression of alkaline phosphatase (ALP) was assessed by immunohistochemistry and the number of osteoclasts
was shown by Tartrate-resistant acid phosphatase (TRAP) staining.
Results: LPS decreased the osteogenic differentiation of human PDLSCs through TLR4 regulated nuclear factor (NF)-κB
pathway, but not for BMMSCs. Blocking TLR4 or NF-κB signaling partially reversed the decreased osteogenic potential
of PDLSCs and prevented the alveolar bone loss caused by LPS experimental periodontitis in rats. The ALP expression
in the periodontal ligament was elevated after treatment with anti-TLR4 antibody or pyrrolidinedithiocarbamate,
whereas there was no statistical significance among groups for the number of osteoclasts.
Conclusions: These data suggest that LPS can activate TLR4 regulated NF-κB pathway of human PDLSCs, thus
decreasing their osteogenic potential. Blockage of TLR4 or NF-κB pathway might provide a new approach for
periodontitis treatment.* Correspondence: yznmbk@fmmu.edu.cn; yanjin@fmmu.edu.cn
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Periodontitis is characterized by the inflammatory reaction
of the surroundings of the teeth, mostly caused by an oral
microbial biofilm and perpetuated by an uncoordinated
immune-inflammatory response, which ultimately leads to
progressive destruction of the tissues supporting the teeth
[1]. It is until now the major cause of tooth loss and is
associated with a number of systemic diseases, such as
diabetes and cardiovascular diseases [2], while no appro-
priate method has been developed to provide a functional
and predictable method for periodontal regeneration.
Lipopolysaccharide (LPS), a cell wall component of gram-
negative bacteria, is mainly recognized by toll-like receptor
4 (TLR4) of the host. This bimolecular compound pene-
trates periodontal tissue [3,4] and is considered to be a
major nexus for virulence in periodontitis [5,6]. Previously,
numerous studies have been conducted to examine the
role of LPS in periodontal pathogenesis. However, the
underlying molecular mechanism of LPS-host interaction
is still unclear.
Mesenchymal stem cells play a key role in the main-
tenance of the regenerative capacity of periodontal tis-
sue. The discovery of periodontal ligament stem cells
(PDLSCs), which form a cementum/PDL-like structure
after in vivo transplantation, provides a new prospect
for periodontal tissue regeneration [7]. After transplant-
ation, PDLSCs effectively regenerated the alveolar bone
in the defects created by surgical bur in miniature pigs,
showing encouraging results in preclinical trials [8,9].
In addition, bone marrow mesenchymal stem cells
(BMMSCs), originated from bone marrow, also have
been documented to possess the capacity to regenerate
periodontal tissue in various animal models [10,11].
However, in a diseased periodontal environment, tissue
repair does not occur naturally because of the lack of
robust stem cells, which leads to the loss of periodon-
tal tissue including cementum/periodontal ligament
and the alveolar bone [12]. Repair of the alveolar bone
is considered to be controlled by the stem cells in the
niche area, such as PDLSCs or BMMSCs. However, the
toxic product of bacteria, LPS, is elevated in the oral
cavity of periodontitis patients [13] and it may affect
the bone regeneration capacity of PDLSCs and BMMSCs.
Up to now, controversial findings have been reported
regarding the role of LPS and TLR4 in the osteogenic
differentiation of BMMSCs [14-16]. In addition, there
are still no reports on the expression of TLR4 in PDLSCs
and the influence of LPS on the osteogenic differentiation
of PDLSCs. In this study, we sought to comparatively
investigate the influence of LPS on the osteogenesis po-
tential of PDLSCs and BMMSCs and further explore
the mechanisms of LPS regulation of the osteogenic
differentiation of these two kinds of MSCs. The results
indicated that LPS decreased the osteogenic potential ofPDLSCs through the TLR4 regulated NF-κB pathway,
but not that of BMMSCs. Blocking the TLR4 or NF-κB
pathway partially reversed the impaired osteogenic po-
tential of PDLSCs after LPS treatment and prevented
the alveolar bone loss induced by LPS in experimental
periodontitis in rats.Materials and Methods
Isolation of PDLSCs
Healthy human third molars were extracted from five
systemically healthy adults (25 to 30 years of age) at
the Department of Periodontology and Oral Medicine,
Stomatological Hospital of the Fourth Military Medical
University. Written consent was obtained from them
prior to conducting the study. Ethical approval had been
obtained from the Ethics Committee of the School of
Stomatology, Fourth Military Medical University.
PDLSCs were isolated and cultured as we previously
described [17,18]. PDL (periodontal ligament) tissues were
scraped off the middle third of the root surface and then
digested with collagenase I (3 mg/ml; Sigma–Aldrich, St.
Louis, MO, USA) for two hours at 37°C to obtain single
cell suspensions. Cells were maintained in α-minimal
essential medium (α-MEM; Sigma–Aldrich) with 10%
fetal bovine serum (FBS; Thermo Electron, Melbourne,
Australia), 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin, and incubated at 37°C in 5%
CO2. The medium was changed every three days. Single
cell-derived colony cultures were obtained using the
limiting dilution technique, and different colonies were
gathered as passage 0 (P0) cells. To avoid changes in cell
behavior caused by prolonged culture, only cells from
P3 to P5 were used in this study.Isolation of BMMSCs
Bone marrow was harvested from the iliac crest of three
healthy volunteers (25 to 30 years of age). Written con-
sent was obtained from them prior to conducting the
study. Ethical approval had been obtained from the Ethics
Committee of the School of Stomatology, Fourth Milita-
ry Medical University. Mononuclear cells were isola-
ted by density gradient centrifugation (TBD, Tianjin,
China), washed in PBS and seeded at 2 × 104 cells/cm2
in α-MEM (Sigma–Aldrich) with 10% FBS (Thermo
Electron), 2 mM L-glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin, and incubated at 37°C in 5%
CO2. After 48 hours, non-adherent cells were removed
by washing and the medium was changed every three
days. At sub-confluence, the cells were detached by
0.25% trypsin and counted. For passages, cells were
replated in 75 cm2 flasks in the same culture condi-
tions until sub-confluence. The cells of passage 3 to 5
were used for the following experiments.
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Total cellular RNA was extracted by TRIzol reagent
(Invitrogen, Eugene, OR, USA) according to the manu-
facturer’s instructions. Isolated total RNA was then sub-
jected to reverse transcription using OligodT primer and
PrimeScript® RTase (Takara, Dalian, China) according to
the manufacturer’s instructions. Quantitative RT-PCR
(qRT-PCR) was performed with SYBR® Premix Ex Taq™
II (Takara, Dalian, China) using the C1000TM Thermal
Cycler (Bio-Rad, Hercules, CA, USA).
The primers used in this study were as follows: TLR1:
forward, 5′-CAGTTACTCCCGGAGGCAATGCT-3′, and
reverse, 5′-AGATTCCTTTTGTAGGGG TGCCCA-3′;
TLR2: forward, 5′-TTGTGCCCATTGCTCTTTCA- 3′,
and reverse, 5′-GCTTCAACCCACAACTACCAGTT-3′;
TLR3: forward, 5′-CACGGCTCTGGAAACA CGCA-3′,
and reverse, 5′-AGGTTCCTGAAAGCTGGCCCGA-3′;
TLR4: forward, 5′- ACCTGATGCTTCTTGCTGGCT
GC- 3′, and reverse, 5′-AGCAATGGCCACACCGG
GAA-3′; TLR5: forward, 5′-CCTCTGCCCCTAGAA
TAAGAACATA-3′, and reverse, 5′-TGATCCTCGTT
GTCCTAGCAGAA-3′; TLR6: forward, 5′-AGCCACT
GCAACATCA TGACCAA- 3′, and reverse, 5′-TG
TCAGAGACCTGAAGCTCAGCGA-3′; TLR7: for-
ward, 5′-GGAAATTGCCCTCGTTGTTA-3′, and re-
verse, 5′-CTGGGGAGAAAATG CAGAAA-3′; TLR8:
forward, 5′-GAGTTATGCGCCGAAGAAAATT-3′, and
reverse, 5′-TTTCTCATCACAAGGATAGCTTCTAG
AA-3′; TLR9: forward, 5′-AGGCCTGAGGC GGTT
TGATCT-3′, and reverse, 5′-GGTGTGCAGGCGGTT
CTG-3′; TLR10: forward, 5′-GGCCAGAAACTGTG
GTCAAT- 3′, and reverse, 5′-AACTTCCTGGCAGCT
CTGA A-3′; Runx2: forward, 5′-CCCGTGGCCTTC
AAGGT -3′, and reverse, 5′- ATGACAGT ACCGCCC
ATTGC- 3′; β-actin: forward, 5′-CTCCACCCTGG
CCTCGCTGT-3′, and reverse, 5′- GCTGTCACCTTC
ACCGTTCC- 3′. The expression levels of the target
genes were normalized to that of the housekeeping gene
β-actin.
In vitro osteogenic assay
PDLSCs or BMMSCs were analyzed for their capacity to
differentiate toward osteogenic lineages. Cells were seeded
in six-well culture plates at a density of 2 × 105 cells/well.
Osteogenic medium was α-MEM supplemented with 10%
FBS, 100 nM dexamethasone, 5 mM β-glycerophosphate
(Sigma-Aldrich) and 50 μg/ml L-ascorbic acid (Sigma-
Aldrich). Cells cultured in induction medium additionally
supplemented with LPS (10 μg/ml, O55:B5, Sigma-
Aldrich) were used as the experimental group. The in-
duction medium was changed every three days. At day
14, total RNA was extracted for the analysis of osteo-
genic gene (Runx2) by qRT-PCR. At day 28, the samples
were fixed with 4% polyoxymethylene for 20 minutes.The osteogenic differentiation was assessed using Alizarin
red S (Sigma-Aldrich) staining. For Alizarin red quantifi-
cation, 1 ml of 10% cetylpyridinium chloride was added
to each well. Light absorbance of the extracted dye was
measured at 620 nm.
Protein isolation and western blot analysis
Total proteins were extracted with lysis buffer (10 mM
Tris–HCl, 1 mM ethylenediaminetetraacetic acid (EDTA),
1% sodium dodecyl sulfate, 1% Nonidet P-40, 1:100 pro-
teinase inhibitor cocktail, 50 mM β-glycerophosphate,
50 mM sodium fluoride) (Beyotime, Shanghai, China).
The protein concentration was determined with a protein
assay kit (Beyotime) following the manufacturer’s instruc-
tions. Aliquots of 40 to 50 μg per sample were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred to polyvinylidene fluor-
ide (PVDF) membranes (Millipore, Billerica, MA, USA)
and blocked with 5% bovine serum albumin (BSA) in
PBST (PBS with 0.1% Tween), then incubated with
the following primary antibodies overnight: anti-TLR4,
anti-β-actin (Abcam, Cambridge, UK), anti-NFκBp65,
anti-phospho-NFκBp65, anti-IκBα and anti-phospho-
IκBα (Cell Signaling Technology, Beverly, MA, USA).
Then, the membranes were incubated with horserad-
ish peroxidase-conjugated secondary antibody (Boster,
Wuhan, China). The blots were visualized using an en-
hanced chemiluminescence kit (Amersham Biosciences,
Piscataway, NJ, USA) according to the manufacturer’s
instructions.
anti-TLR4 antibody/PDTC treatment
The mechanisms involved in the influence of TLR4
ligation on the osteogenic potential of PDLSCs and
BMMSCs, were studied using the TLR4 antagonist anti-
TLR4 antibody (0.5 μg/ml) and the NF-κB inhibitor pyrro-
lidinedithiocarbamate (PDTC, 40 ng/ml, Sigma-Aldrich).
Cells were seeded in six-well culture plates at a density of
2 × 105 cells/well and expanded in α-MEM (10% FBS)
until reaching 80% confluence; then, the culture medium
was changed to osteogenic medium with or without LPS
(10 μg/ml). For the anti-TLR4 antibody group, anti-TLR4
antibody was added four hours before changing the
medium from basal medium to osteogenic induction
medium containing LPS (10 μg/ml). For the PDTC group,
PDTC was added at the time of changing to the osteo-
genic medium (containing LPS). Medium was changed
every three days. Cells were cultured for 3, 14 and 28 days,
and then subjected to assays for western blot or in vitro
osteogenic differentiation, respectively.
Induction of experimental periodontitis
Experimental periodontitis was inducted as previously
described [19]. All animal procedures were performed
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tee of the Fourth Military Medical University, Xi’an,
China. Twelve adult male Sprague–Dawley rats (SD rats,
250.7 ± 20.5 g, obtained from the Laboratory Animal Re-
search Centre of the Fourth Military Medical University)
were used in this protocol. The test group rats were
injected with 10 μl of Escherichia coli LPS (1 mg/ml)
into the maxillary palatal gingiva between the first and
second upper molars. The LPS injections were repeated
every other day on three separate days. The control
group rats received 10 μl of saline injection according to
the same schedule as the LPS-injected rats.
Administration of drug and assessment of alveolar
bone loss
Twelve rats were randomly distributed into four groups
of three rats each: 1) saline: gingiva was injected with
saline; 2) LPS: gingiva was injected with LPS; 3) LPS +
anti-TLR4: gingiva was injected with LPS and TLR4
neutralizing antibody (5 μg/ml); and 4) LPS + PDTC:
gingiva was injected with LPS and the NF-κB blocking
reagent PDTC (400 ng/ml). On day 7, all rats were anes-
thetized and euthanized by exsanguination. The whole
head was removed and the maxillary jaws were scanned
and analyzed using a micro-CT system (Siemens Inveon
Micro CT, Munich, Germany). The alveolar bone height
was measured at 17 different sites (three sites for each
of five roots and one site for each root furcation of two
teeth) in the maxillary molar regions by recording the
distance from the cemento-enamel junction (CEJ) to
the alveolar bone crest, using the built-in software. Then,
samples were harvested, fixed in 4% paraformaldehyde
and decalcified with 5% EDTA before paraffin embedding
for further use.
Immunohistochemistry
To quantify the osteogenic potential of periodontal
ligament tissue, the expression of alkaline phosphatase
(ALP) was assessed by immunohistochemistry. Paraffin-
embedded tissue sections were de-waxed in xylene and
rehydrated through graded alcohols to water. Endogenous
peroxidase was blocked using 3% H2O2 for 15 minutes. For
antigen retrieval, 0.3% trypsin (Sigma–Aldrich) was used
for 15 minutes. Sections were blocked with 10% serum for
30 minutes. Slides were incubated with primary antibody
anti-ALP (Abcam, 1:200 dilution) for two hours. Goat anti-
rabbit secondary antibody was applied for one hour at
room temperature. Sections were then incubated in strept
avidin-biotin complex (SABC) (Boster) for 30 minutes.
Diaminobenzidine (DAB) solution was applied for two to
five minutes and development of the color reaction was
monitored microscopically. Slides were counterstained
with hematoxylin, dehydrated, cleared and then mounted.
The slides were observed under a light microscope(BX-51, Olympus, Japan), and images were acquired using
a CDD camera. Quantification of ALP-positive staining
was carried out using the software of Image-Pro Plus 6.0.
Tartrate-resistant acid phosphatase staining of rat
alveolar bone section
To quantify osteoclast activity, mature osteoclasts were de-
termined by tartrate-resistant acid phosphatase (TRAP)-
positive cells on the bone surface. Deparaffinized sections
were refixed with a mixture of 50% ethanol and 50% acet-
one for 10 minutes. TRAP staining solutions (1.6% naph-
thol AS-BI phosphate in N, N-dimethylformamide, 0.14%
fast red-violet LB diazonium salt, 0.097% tartaric acid, and
0.04% MgCl2 in 0.2 M sodium acetate buffer at pH 5.0)
were freshly made. The sections were incubated in the solu-
tion for 30 minutes at 37°C under a shield and counter-
stained with toluidine blue. All regents for TRAP staining
were purchased from Wako Pure Chemical Industries
(Code No. 294–67001, Chuo-ku, Osaka, Japan). The slides
were observed under a light microscope (BX-51, Olympus,
Tokyo, Japan), and images were acquired using a CDD
camera. Quantification of TRAP-positive osteoclasts was
carried out by the software of Image-Pro Plus 6.0.
Statistical analysis
All experiments were repeated at least three times and
data are presented as mean ± SD. To test the statistically
significant differences between paired observations, the
Student’s t-test for paired data was used. All statistical
analyses were performed using SPSS software, version
16.0. P value <0.05 was considered statistically significant.
Results
TLR4 expression of PDLSCs and BMMSCs with or without
LPS treatment
To compare the TLRs (TLR1 to TLR10) expression profile
of PDLSCs and BMMSCs, we measured their gene expres-
sion level by quantitative RT-PCR. Differentially, PDLSCs
showed stronger gene expression of TLR1, TLR2 and
TLR5 (Figure 1A, P <0.05), while BMMSCs showed stron-
ger gene expression for TLR3, TLR4, TLR6, TLR8, TLR9
and TLR10 (Figure 1A, P <0.05). In addition, PDLSCs and
BMMSCs both showed strong expression of TLR3 and we
did not detect the expression of TLR7 in either of them.
However, the expression of TLR4 in PDLSCs was much
less than that in BMMSCs.
To further compare the protein expression of TLR4 in
PDLSCs and BMMSCs with or without LPS treatment,
Western blot assay was performed to measure the pro-
tein expression of TLR4. The results showed that
PDLSCs and BMMSCs had similar TLR4 protein expres-
sion and TLR4 expression was not changed significantly
either at 0.5 or 1 hour after LPS simulation (Figure 1B,C).
Figure 1 TLR4 expression of PDLSCs and BMMSCs with or without LPS treatment. (A) Relative gene expression of TLRs (TLR1 to TLR10) of
PDLSCs and BMMSCs was analyzed by qRT-PCR. Relative gene expression of TLRs was determined based on the threshold cycle (CT) values. The
expression levels of the target genes were normalized to that of the housekeeping gene β-actin. PDLSCs (*P <0.05 versus PDLSCs, n = 3), BMMSCs
(n = 3). (B) Western blot analysis showed the protein expression of TLR4, and β-actin was used as the internal control. (C) Relative intensity of the
tested protein was quantitatively analyzed using the Adobe Photoshop CS2 software. Data represent the means ± SD (n = 3). BMMSCs, bone marrow
mesenchymal stem cells; LPS, lipopolysaccharide; PDLSCs, periodontal ligament stem cells; SD, standard deviation; TLR4, Toll-like receptor 4.
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activates the NF-κB pathway in both PDLSCs and
BMMSCs
To identify the role of LPS in regulating the osteogenic
differentiation of PDLSCs, LPS (10 μg/ml) was added to
the osteogenic induction medium. Alizarin red S staining
showed that LPS impaired the osteogenic differentiation
ability of PDLSCs, which was demonstrated by the de-
creased formation of mineralized nodules compared with
the control group after four weeks induction (Figure 2A).
However, the formation of mineralized nodules of
BMMSCs was not changed after LPS treatment, which
suggests that LPS did not influence the osteogenicpotential of BMMSCs (Figure 2A). LPS also significantly
down regulated the expression of the osteogenic related
gene Runx2 in PDLSCs compared with the control group
(P <0.05, Figure 2B). In accordance with the results of
Alizarin red S staining of BMMSCs, the expression of
Runx2 after LPS treatment was not changed significantly
compared with the control group (Figure 2B).
The common signaling feature of TLR4 is the activation
of the transcription factor nuclear factor-κB (NF-κB). To
ascertain the role of LPS in the activation of the TLR4
mediated NF-κB pathway of PDLSCs and BMMSCs, we
stimulated PDLSCs and BMMSCs by LPS for 0.5 and
one hour, respectively. Western blot analysis showed
Figure 2 LPS impairs the osteogenic potential of PDLSCs and activates the NF-κB pathway in PDLSCs and BMMSCs. (A) PDLSCs and
BMMSCs treated with or without LPS were cultured in osteogenic medium and osteogenic differentiation was determined by Alizarin red S
staining after 28 days. Alizarin red was then extracted and measured for light absorbance at 620 nm. (B) Gene expression of Runx2 in PDLSCs
and BMMSCs with or without LPS treatment was measured by qRT-PCR after osteogenic induction for 14 days. (C) Western blot analysis showed
the protein expression of phospho-IκBα, IκBα, phospho-NFκBp65 and NFκBp65, and β-actin was used as the internal control. (D, E) Relative
intensity of the tested protein was quantitatively analyzed using Adobe Photoshop CS2 software. Data represent the means ± SD. * P <0.05
(n = 3). BMMSCs, bone marrow mesenchymal stem cells; LPS, lipopolysaccharide; NF-κB, nuclear factor κB; PDLSCs, periodontal ligament stem cells;
SD, standard deviation.
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and BMMSCs was increased after LPS treatment for 0.5
and one hour (P <0.05, Figure 2C,D,E). The expression
of phospho-NF-κBp65 in both PDLSCs and BMMSCs
increased dramatically after LPS treatment for one hour
(P <0.05, Figure 2C,D,E). Total IκBα and NF-κBp65
were not changed significantly after LPS stimulation
(Figure 2C,D,E). Since phosphorylation of IκBα results
in the release and nuclear translocation of active NF-κB,
these data suggested that LPS can activate TLR4 medi-
ated NF-κB signaling in both PDLSCs and BMMSCs.TLR4 or NF-κB blockage reverses the impaired osteogenic
differentiation of PDLSCs stimulated by LPS
To document the involvement of TLR4 and its down-
stream NF-κB signaling pathway in the process of LPS
impairment of the osteogenic potential of PDLSCs, anti-
TLR4 antibody and the NF-κB inhibitor PDTC were
added to the differentiation medium to block the effect
of LPS, respectively. Western blot analysis showed that
anti-TLR4 antibody or PDTC effectively decreased the
expression of phospho-NF-κBp65 in the presence of LPS
both in PDLSCs and BMMSCs (P <0.05, Figure 3A,B).
Figure 3 Anti-TLR4 antibody or PDTC effectively blocks the activated NF-κB pathway activated by LPS. (A) The TLR4 antagonist anti-TLR4
antibody (0.5 μg/ml) and the NF-κB inhibitor PDTC (40 ng/ml) were incubated with PDLSCs or BMMSCs, which were stimulated by LPS. After
72 hours, western blot showed that the expression of phospho-NFκBp65 was reduced. β-actin was used as the internal control. (B, C) The relative
intensity of the tested protein was quantitatively analyzed using Adobe Photoshop CS2 software. Data represent the means ± SD. * P <0.05
(n = 3). BMMSCs, bone marrow mesenchymal stem cells; LPS, lipopolysaccharide; NF-κB, nuclear factor κB; PDLSCs, periodontal ligament stem cells;
PDTC, pyrrolidinedithiocarbamate; SD, standard deviation; TLR4, Toll-like receptor 4.
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expression of Runx2 in PDLSCs increased significantly
after anti-TLR4 antibody or PDTC treatment (P <0.05,
Figure 4A,D). Accordingly, the decreased mineralized
nodules of PDLSCs following LPS stimulation were also
partially reversed after anti-TLR4 antibody or PDTC
treatment as assayed by Alizarin red S staining (P <0.05,
Figure 4B,E).
However, the gene expression of Runx2 of BMMSCs
was not changed significantly in the presence of anti-
TLR4 antibody or PDTC compared with LPS treatment
alone (Figure 4A,D), and TLR4 blockage or inhibition of
NF-κB did not alter the formation of mineralized nod-
ules of BMMSCs (Figure 4C,F). These results indicated
that LPS dampened the osteogenic differentiation of
PDLSCs through the TLR4 regulated NF-κB pathway,
but not through that of BMMSCs.
Blockage of TLR4 or NF-κB pathway effectively prevents
alveolar bone loss caused by LPS
Previous studies have documented that experimental
periodontitis can be induced by injection of LPS to SD
rats and alveolar bone loss was observed in this model
[19,20]. Our results above indicated that blocking TLR4or NF-κB could enhance the osteogenic differentiation
of PDLSCs after LPS treatment. We hypothesized that
blockage of TLR4 or NF-κB would also prevent alveolar
bone loss in LPS induced experimental periodontitis.
Micro-CT analysis showed that LPS can cause obvious
alveolar bone loss, and the most obvious bone loss pos-
ition was just between the first and second maxillary
molars, where we injected LPS directly (Figure 5A). Be-
cause of the existence of drug diffusion, we tested 17
sites of the first and second maxillary molar regions
using a previously described method [19]. We found
that, in the LPS group, the distance from the CEJ to the
alveolar bone crest at nearly all 17 sites tested was the
highest (Figure 5B), which meant that the bone loss in
this group was the greatest. With the administration of
anti-TLR4 antibody or PDTC, the alveolar bone loss be-
tween the first and second maxillary molars was obvi-
ously reduced (Figure 5A), and the distance from the
CEJ to the alveolar bone crest was reduced (Figure 5B).
Statistical analysis of the average bone loss for the 17
sites in each group also showed that anti-TLR4 antibody
or PDTC significantly reversed the bone loss caused by
LPS (Figure 5C). The average bone loss in each group was:
1) saline = 0.62 ± 0.06; 2) LPS = 0.95 ± 0.07; 3) LPS +
Figure 4 TLR4 or NF-κB blockage reverses the impaired osteogenic differentiation of PDLSCs stimulated by LPS. (A, D) Gene expression
of Runx2 in PDLSCs and BMMSCs with or without drug treatment was measured by qRT-PCR after osteogenic induction for 14 days. (B, E) The
impaired osteogenic differentiation of PDLSCs caused by LPS was reversed by anti-TLR4 antibody or PDTC. Osteogenic differentiation was determined
by Alizarin red S staining after osteogenic induction for 28 days and alizarin red was then extracted and measured for light absorbance at 620 nm.
(C, F) The osteogenic differentiation of BMMSCs with or without drug treatment was determined by Alizarin red S staining after osteogenic induction
for 28 days. Data represent the means ± SD. *P <0.05 (n = 3). BMMSCs, bone marrow mesenchymal stem cells; LPS, lipopolysaccharide; NF-κB, nuclear
factor κB; PDLSCs, periodontal ligament stem cells; PDTC, pyrrolidinedithiocarbamate; SD, standard deviation; TLR4, Toll-like receptor-4.
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0.05 (P <0.05, Figure 5C).
ALP expression is elevated and the osteoclast number is
not affected after treatment with anti-TLR4 antibody or
PDTC
To explore if the reduced bone loss was due to the in-
creased osteogenic potential of the periodontal tissue,
we used immunohistochemistry staining to detect ALP
expression. The result showed positive ALP staining in
the periodontal ligament and its expression in the LPSgroup was significantly reduced compared to that of the
control group (P <0.05, Figure 6). After anti-TLR4 anti-
body or PDTC administration, the ALP expression was
greatly elevated and was comparable to that of the con-
trol group (Figure 6).
To further explore if the reduced bone loss was due to
the reduced osteoclastogenesis of the periodontal tissue,
we checked the number of osteoclasts in the alveolar
bone. TRAP staining showed no significant differences
in terms of mature osteoclast number among the four
groups (Figure 7).
Figure 5 Blockage of the TLR4 or NF-κB pathway effectively reduces the bone loss caused by LPS in vivo. (A) Bone loss in the saline
group, LPS group, LPS + anti-TLR4 group and LPS + PDTC group. (B) Alveolar bone loss determination of maxillary molars. Seventeen sites per
quadrant (three sites for each of five roots and one site for each root furcation of two teeth) were analyzed morphometrically. (C) Mean alveolar
bone loss. Data represent the means ± SD. *P <0.05 (n = 3). LPS, lipopolysaccharide; NF-κB, nuclear factor- κB; PDTC, pyrrolidinedithiocarbamate;
SD, standard deviation; TLR4, Toll-like receptor 4.
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Periodontal regeneration involves the regeneration of
cementum, periodontal ligament and alveolar bone. The
osteogenic differentiation properties of PDLSCs and
BMMSCs are considered to be important during this
process. Understanding the factors and mechanisms
modulating their capacity for bone regeneration is cru-
cial for the treatment of periodontitis. In this study, we
showed that functional TLR4 was expressed by both
PDLSCs and BMMSCs. LPS decreased the osteogenic
differentiation potential of PDLSCs through a TLR4-
mediated NF-κB signaling pathway, but not that of
BMMSCs. In addition, blockage of TLR4 or NF-κB sig-
naling prevented the alveolar bone loss caused by LPS,
which may provide a new clue for periodontitis therapy.
Host recognition of microbes is largely mediated by
TLRs, which are a kind of conserved receptor familyincluding thirteen kinds of TLR subtypes (10 in human
and 12 in mice). They recognize a wide variety of
pathogen-associated molecular patterns in bacteria, vi-
ruses and fungi, as well as certain host-derived mole-
cules [21]. Numerous studies have reported that TLRs
are expressed in periodontal tissue and play an important
role in immune response and the maintenance of peri-
odontal health [22-25]. Mesenchymal stem cells (MSCs)
express TLRs and TLRs ligation can differently affect the
functions of MSCs depending on their tissue origin
[16,26]. BMMSCs and PDLSCs are two kinds of MSCs
from different origins and mediate the regeneration of
periodontal tissue. The expression profile of TLRs in
PDLSCs and the influence of TLR ligation on these cells
have not been studied yet. Thus, in this study, we tested
the expression of TLRs on PDLSCs and found that
PDLSCs showed different TLR gene expression compared
Figure 6 ALP expression is elevated after treatment with anti-TLR4 antibody or PDTC. (A) ALP positive staining was seen in the periodontal
ligament and its expression in the LPS group was significantly reduced compared to that of the control group. After anti-TLR4 antibody or
PDTC administration, the ALP expression was greatly increased and was comparable to that of the control group. (B) Quantification of
ALP-positive staining. Integrated intensity was measured by Image-Pro Plus 6.0. Scale bar: 125 μm. Data represent the means ± SD. (*P <0.05
versus saline group, n = 3). ALP, alkaline phosphatase; LPS, lipopolysaccharide; PDTC, pyrrolidinedithiocarbamate; SD, standard deviation; TLR4,
Toll-like receptor 4.
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file of TLRs on BMMSCs are in accordance with a previ-
ous report [27]. Although PDLSCs showed less TLR4 gene
expression compared with that of BMMSCs, we further
found that PDLSCs and BMMSCs showed similar protein
expression of TLR4. The discrepancy between the gene
and protein expression might be caused by different post-
transcriptional modification or different degradation speed
of the TLR4 protein.
TLR4 recognizes LPS from gram-negative bacteria,
which are the most important factor involved in peri-
odontitis. TLR4 ligation can affect the functions of
MSCs. However, contradictory results have been re-
ported about the osteogenic differentiation of BMMSCs
controlled by LPS/TLR4 signaling. One previous study
showed that TLR4 activation had no effect on osteogenicdifferentiation of human BMMSCs [14]. However, others
reported increased osteogenic differentiation of human
BMMSCs after LPS stimulation [15]. We found that LPS
can activate the TLR4-mediated NF-κB signaling, but the
activated NF-κB signaling caused by LPS did not change
the osteogenic differentiation of BMMSCs. Our results
also showed that the osteogenic differentiation of PDLSCs
was impaired by LPS as demonstrated by the decreased
formation of mineralized nodules and decreased expres-
sion of the osteogenic differentiation gene Runx2. This
might be caused by different cell origins of these two kinds
of MSCs. Furthermore, blockage of TLR4 by TLR4 anti-
body reversed the impaired osteogenic differentiation of
PDLSCs, although not totally. A previous study also
showed that TLR4 neutralizing antibody could not pro-
duce a 100% blockage of TLR4 even during short-term
Figure 7 The number of osteoclasts does not change after anti-TLR4 antibody or PDTC treatment. (A) TRAP staining showed no significant
differences in the number of osteoclasts in the alveolar bone among the saline, LPS, LPS + anti-TLR4 antibody and LPS + PDTC groups. Arrowheads,
TRAP-positive osteoclasts (purple cells). (B) Quantification of TRAP-positive osteoclasts. Integrated intensity was measured by Image-Pro Plus 6.0. Scale
bar: 50 μm. Data represent the means ± SD (n = 3). LPS, lipopolysaccharide; PDTC, pyrrolidinedithiocarbamate; SD, standard deviation; TLR4,
Toll-like receptor 4; TRAP, tartrate-resistant acid phosphatase.
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genic induction was a long ex vivo process, which might
prevent the antibody fully exerting its effects.
The common signaling feature of TLR4 is the activa-
tion of the transcription factor NF-κB, which has been
implicated in controlling the expression of inflammatory
cytokines and the maturation of inflammatory molecules
[29]. We found that LPS activated the NF-κB pathway in
both PDLSCs and BMMSCs. Previous research in our
lab has indicated that NF-κB signaling plays a central role
in regulating the osteogenic differentiation of PDLSCs in
inflammatory microenvironments [30]. To ensure the
involvement of NF-κB signaling in impairing the osteo-
genic differentiation of PDLSCs caused by LPS, we used
PDTC to block the NF-κB pathway and the osteogenicdifferentiation of PDLSCs was reversed. However, the
osteogenic differentiation of BMMSCs was unchanged
in the presence of PDTC. This means that PDTC, even
though it can effectively block NF-κB, does not affect
the osteogenic differentiation of BMMSCs stimulated
by LPS. Interestingly, Hess et al. [31] also found that a
genetic block of the NF-κB pathway did not interfere
with the osteogenic differentiation of BMMSCs. The re-
lationship between the NF-κB pathway and the osteo-
genic differentiation of MSCs is still controversial
[31-35]. In the current study, we found that the NF-κB
pathway was activated in both PDLSCs and BMMSCs
after LPS treatment, but with different influences on the
osteogenic differentiation potential. For allogeneic tis-
sue regeneration, BMMSCs seem like a better candidate
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as indicated by our results. However, several reports
have demonstrated that PDLSCs possess unique peri-
odontal regeneration capacities compared with other
MSCs. Fang et al. [36] reported that human PDLSCs
can generate significant amounts of collagen fibers after
being subcutaneously transplanted with a collagen-based
gelatin sponge into mice, while BMMSCs did not. More-
over, unlike BMMSCs and dental pulp stem cells, mouse
PDLSCs seeded onto tooth root surfaces formed PDL-like
tissue, including well-oriented fibers similar to Sharpey
fibers [37]. Accordingly, PDLSCs may have an advan-
tage as a promising cell source for functional PDL tissue
regeneration, even though their osteogenic potential
can be affected by TLR4 ligation.
TLRs act as a double-edged sword and it is still uncer-
tain which specific signaling pathways need to be blocked
to attenuate the pathology or enhanced to promote host
defense [38]. Here we found that blockage of the TLR4
or NF-κB pathway could partially reverse the osteogenic
differentiation of PDLSCs stimulated by LPS in vitro.
However, the influence of TLR4 or NF-κB blockage
in vivo on the pathogenesis of periodontitis is still un-
known. In this study, we found that the alveolar bone
loss caused by LPS was reduced after treatment with
TLR4 antibody or NF-κB inhibitor, with elevated ALP
expression and unchanged TRAP-staining. Thus, we
speculated that the reduced alveolar bone loss was due
to the elevated regeneration of the periodontal ligament.
Nevertheless, the detailed mechanism still needs further
investigation, as the mechanism of LPS induced peri-
odontitis is complicated and not completely under-
stood. It is hypothesized that LPS can activate the host
cells in the periodontium, including polymorphonuclear
leukocytes, macrophages, fibroblasts and the epithelium,
mediated by TLR4 [19]. In addition, LPS can induce alveo-
lar bone loss by stimulating the secretion of proinflamma-
tory cytokines (IL-1β, TNF-α or IL-6) and the formation
of osteoclasts [39]. LPS can also induce the secretion of
matrix metalloproteinases (MMPs), causing direct damage
to periodontal tissues [40]. Although we can not preclude
other effects, which reduced the alveolar bone loss, the
attempt to block the TLR4 or NF-κB pathway to treat
periodontitis shows encouraging results.
No report so far has described the clinical application
of the TLR4 antibody, but there is already a phase I
study recruiting for assessing the safety of a human anti-
TLR4 monoclonal antibody (NI-0101), which is spon-
sored by NovImmune SA. NF-κB can be activated by
TLR4 ligation and because of its pivotal role in inflam-
mation and cell proliferation, much attention has been
given to strategies that inhibit NF-κB activity. Most of
the drugs that are currently used for treating inflamma-
tory conditions, such as non-steroidal anti-inflammatorydrugs (NSAIDs), disease-modifying anti-rheumatic drugs,
cyclosporine A and corticosteroids, have inhibitory effects
on NF-κB activity [41]. There are also other more highly
specific pharmacological NF-κB inhibitors, such as PDTC
and flavopiridol [42,43]. Periodontitis is an infectious dis-
ease, and how to choose the appropriate TLR4 antibody
or NF-κB inhibitors to inhibit the excessive inflammation
reaction on the one hand and maintain necessary immune
reaction to eliminate pathogens on the other hand is a mat-
ter of great concern, which needs further investigation.
Conclusions
Our research demonstrated that the NF-κB pathway activated
by TLR4 ligation mediates the impairment of osteogenic dif-
ferentiation of PDLSCs. Blockage of TLR4 or the NF-κB
pathway can prevent the alveolar bone loss caused by LPS
in vivo. Our findings suggest that TLR4 or the NF-κB path-
way might serve as a new therapeutic target for periodontitis.
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